Practice-changing data in endometrial cancer support checkpoint inhibitor–chemotherapy combinations, extending ...

PAGADIAN CITY, Zamboanga del Sur – Ten members of the Society of Gynecologic Oncologists of the Philippines Foundation, Inc. ...

Gynecologic cancers affect thousands of women each year, yet many remain difficult to detect in their earliest stages.

Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), ...

Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy Topline data ...

Detailed price information for Citius Pharmaceuticals Inc (CTXR-Q) from The Globe and Mail including charting and trades.

Ready to declutter? The Cancer horoscope for March 16th reveals why silence is the key to relationship harmony today and how ...

Citius Oncology reports positive results from phase 1 study of Lymphir in combo with pembrolizumab in relapsed or refractory gynaecologic cancers: Cranford, New Jersey Friday, Mar ...

The phase 3 KEYNOTE‑B96 trial showed that Keytruda plus paclitaxel, with or without Avastin, improved overall survival in patients with platinum‑resistant ovarian cancer. From your perspective, what ...

An Omaha woman diagnosed with endometrial cancer days before her 43rd birthday is now partnering with her oncologist to raise awareness about a disease she says too many women are embarrassed to ...

"I dismissed my fear as paranoia. But, deep down, I still felt that something was wrong." ...

Women who used fertility treatments had no higher overall risk of invasive cancer than other women, a large Australian study led by researchers from UNSW Sydney has found. The study, published in JAMA ...